Try our Advanced Search for more refined results

In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation

Track this case

Case overview

Case Number:

2:17-md-02785

Court:

Kansas

Nature of Suit:

Personal Inj. Prod. Liability

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

Daniel D. Crabtree

Firms

Companies

Sectors & Industries:

  1. July 01, 2019

    Sanofi Casting Blame For Failed EpiPen Rival, Mylan Says

    Mylan urged a Kansas federal judge Friday to nix Sanofi's antitrust allegations in a broader multidistrict litigation, arguing that its EpiPen competed with Sanofi's epinephrine auto-injector fair and square, only for the latter's product to fail and Sanofi to foist the blame on Mylan.

  2. January 24, 2019

    Sanofi Suit Against Mylan To Stay In EpiPen MDL, For Now

    Sanofi's allegations that Mylan illegally protected its EpiPen monopoly will remain tied into consumers' related multidistrict litigation in Kansas, a federal judge ruled Wednesday, as he found splitting the similar antitrust cases doesn't make sense now, but noted Sanofi's remand chances will look better closer to trial.

  3. December 18, 2018

    EpiPen MDL Gets Special Master To Deal With Disputed Docs

    A Kansas federal court has appointed a special master to settle a discovery dispute between Mylan and Sanofi in multidistrict litigation over EpiPen price hikes after the companies failed to sort out their disagreements over more than 2,000 documents on Sanofi's privilege log.

  4. December 14, 2018

    EpiPen MDL Attys Scolded For 'Mindless Bickering'

    A Kansas federal judge on Friday dressed down attorneys in multidistrict litigation over EpiPen price hikes for engaging in "mindless bickering" during a high-stakes deposition of Mylan NV's chief executive officer.

  5. December 14, 2018

    Sanofi Fires Back Against Mylan In Its Bid To Exit EpiPen MDL

    Sanofi-Aventis US LLC told a Kansas federal court Friday that Mylan Inc. missed the mark when pointing to overlaps between Sanofi's case accusing the EpiPen maker of employing anti-competitive tactics and suits from consumers over prices of the drug, arguing there's enough difference to warrant transferring its case out of multidistrict litigation.

  6. December 03, 2018

    EpiPen Maker Slams Sanofi's Bid To Exit Antitrust MDL

    Sanofi should not yet be allowed to leave multidistrict litigation to pursue claims elsewhere that EpiPen maker Mylan used anti-competitive practices to hurt sales of Sanofi's competing emergency allergy treatment, Mylan told a Kansas federal court Friday.

  7. November 01, 2018

    Sanofi Wants Claims Against Mylan Out Of EpiPen MDL

    Sanofi-Aventis US LLC urged a Kansas federal court on Thursday to recommend its suit accusing EpiPen maker Mylan Inc. of using anti-competitive practices to hurt sales of its competing emergency allergy treatment be transferred out of multidistrict litigation over the drug.

  8. October 02, 2018

    Consumers Seek Sanctions For Mylan In EpiPen Pricing Suit

    A potential class of consumers has asked a Kansas federal judge to sanction Mylan NV for allegedly interfering with discovery and withholding documents and emails that consumers are seeking in an antitrust suit alleging the pharmaceutical company drove up the price of emergency allergy treatment EpiPen.

  9. September 25, 2018

    Sham Petition Suits Are Piercing Big Pharma's Antitrust Shield

    A long-standing U.S. Supreme Court doctrine shielding companies that petition the U.S. Food and Drug Administration from antitrust liability is proving increasingly unhelpful to brand-name drugmakers accused of delaying generic-drug rivals by bombarding the FDA with cockamamie scientific arguments.

  10. September 06, 2018

    Mylan Decries 'Hopeless Fishing Expedition' In EpiPen MDL

    Mylan NV assailed an effort to access more of its CEO’s emails in multidistrict litigation over price hikes for emergency allergy treatment EpiPen, calling the bid a “hopeless fishing expedition” motivated by failures to uncover evidence of C-suite misconduct.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!